Navigation Links
UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema
Date:12/13/2011

MOUNTAIN VIEW, Calif., Dec. 13, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued a final guidance which determined that Novartis AG's drug Lucentis is not as cost effective as conventional laser photocoagulation treatment and rejected the leading drug therapy as a treatment for diabetic macular edema (DME), a swelling of retinal tissue and the most common cause of vision loss in diabetics. The rejection means that the UK National Health Service (NHS) currently will not pay for drug therapy with Lucentis for DME treatment in diabetic patients, thereby creating another important opportunity for advanced laser treatments such as IRIDEX' MicroPulse laser therapy, which has shown to be as effective as conventional laser photocoagulation with no associated retina tissue damage.

NICE, an independent appraisal committee which the UK NHS relies upon, determined that the benefits derived by Lucentis do not justify its cost; and that laser photocoagulation represented better value for NHS resources. "While Novartis is certain to appeal the ruling, this is an important indication that DME patients should consider other options besides drug therapy," noted Dominik Beck, PhD., IRIDEX President and CEO.

"This is a very clear and important statement by one of the most important medical care payers in the world: drugs are not a panacea for retinal diseases," Dr. Beck said. "Drugs like Lucentis certainly have a role in ophthalmology and can be an excellent and safe treatment for acute DME, but in addition to high costs, they come with side effects and questions about their long term benefits. That's among the reasons why we now offer MicroPulse technology on all of our new laser systems and why MicroPulse technology should be considered a first line treatment for most forms of DME. Numerous recent studies show that MicroPulse technology can provide significant durable benefits for diabetes patients without damaging the retina; thus providing powerful economic advantages for both the payors and patients."

DME is a rapidly expanding retinal disorder. Up to 10% of all diabetics will develop DME during their lifetime. Detecting and treating diabetic eye disease with laser therapy can reduce the development of severe vision loss by an estimated 50% to 60%.

About MicroPulse Technology

MicroPulse is a tissue-sparing laser therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

About IRIDEX Corporation

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to opportunities for advanced laser treatments, the Company's MicroPulse technology, the economic and therapeutic benefits of this technology and the Company's growth strategy.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and our Quarterly Reports on Form 10-Q for the quarters ended April 2, 2011, July 2, 2011 and October 1, 2011, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.                                                                                                                                                                    


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Isotopes Inc. Announces Conference Call to Give an Update on the Companys General Business Status
2. NHS National Innovation Centre Estimates Sequana Medicals ALFApump® System Could Save the NHS £50 Million in ascites Care Annually
3. IBM Contributes Data to the National Institutes of Health to Speed Drug Discovery and Cancer Research Innovation
4. New MediCare International Excess Options Give up to 50% Premium Discount
5. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
6. Chindex International, Inc. to Present at the 22nd Annual Oppenheimer Healthcare Conference
7. National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week
8. National Influenza Vaccination Week is December 4 - 10, 2011
9. Bupa International Releases Health Guides to Hong Kong and Singapore
10. Leading Indian CRO Max Neeman International Expands in Response to Positive Biosimilars Market in India
11. National Coalition Continues Fight to Stop the Express Scripts/Medco Merger in Nations Capitol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Research and Markets has announced the addition of the ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory from ... points to easily connect elderly veterans of America's armed forces to a range ... also conveys material on this year's increase in the Veterans Pension with Aid ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):